ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• ErbB2/neu protein (p185) is a key factor in breast cancer development and progression.
• Accurate prognostic markers are crucial for effective breast cancer management.

Purpose of the Study:

• To evaluate the prognostic significance of ErbB2/neu protein (p185) expression in breast cancer patients.
• To determine if p185 levels can differentiate between low-risk and high-risk patient groups.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to quantify p185 expression in 115 breast cancer specimens.
• Patient data were analyzed for correlations between p185 levels, clinico-biological parameters, and clinical outcomes.
• Multivariate analysis was employed to assess the relationship between p185 and disease-free survival.

Main Results:

• p185 expression levels showed distinct patterns when compared to clinico-biological parameters and clinical outcomes.
• Intermediate p185 concentration groups demonstrated significantly better disease-free survival compared to low and high concentration groups (p = 0.02).
• Multivariate analysis confirmed a significant association between grouped p185 levels and disease-free survival, enabling the classification of patients into "low risk" and "high risk" categories.

Conclusions:

• Biochemical determination of p185 may offer a more precise method for identifying high-risk breast cancer patients.
• These preliminary findings suggest p185 quantification as a potential prognostic biomarker in breast cancer.